174 related articles for article (PubMed ID: 16893647)
1. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
[TBL] [Abstract][Full Text] [Related]
2. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase.
Asano T; Yoshikawa T; Nakamura H; Uehara Y; Yamamoto Y
Bioorg Med Chem Lett; 2004 May; 14(9):2299-302. PubMed ID: 15081028
[TBL] [Abstract][Full Text] [Related]
4. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
5. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
6. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
7. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
Gaudette F; Raeppel S; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2010 Feb; 20(3):848-52. PubMed ID: 20071170
[TBL] [Abstract][Full Text] [Related]
8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases.
Asano T; Nakamura H; Uehara Y; Yamamoto Y
Chembiochem; 2004 Apr; 5(4):483-90. PubMed ID: 15185372
[TBL] [Abstract][Full Text] [Related]
10. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenov VV; Milligan D
Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
[TBL] [Abstract][Full Text] [Related]
11. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
[TBL] [Abstract][Full Text] [Related]
12. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
[TBL] [Abstract][Full Text] [Related]
13. Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases.
Asano T; Yoshikawa T; Usui T; Yamamoto H; Yamamoto Y; Uehara Y; Nakamura H
Bioorg Med Chem; 2004 Jul; 12(13):3529-42. PubMed ID: 15186837
[TBL] [Abstract][Full Text] [Related]
14. ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
Kiselyov AS; Piatnitski EL; Samet AV; Kisliy VP; Semenov VV
Bioorg Med Chem Lett; 2007 Mar; 17(5):1369-75. PubMed ID: 17188873
[TBL] [Abstract][Full Text] [Related]
15. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
16. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors.
Hamadeh HK; Todd M; Healy L; Meyer JT; Kwok AM; Higgins M; Afshari CA
Chem Res Toxicol; 2010 Jun; 23(6):1025-33. PubMed ID: 20521778
[TBL] [Abstract][Full Text] [Related]
17. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
18. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
